The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China

被引：0
|
作者：
Shuyan Gu
Jinghong Gu
Xiaoyong Wang
Xiaoling Wang
Lu Li
Hai Gu
Biao Xu
机构：
[1] Nanjing University,Center for Health Policy and Management Studies, School of Government
[2] University of Washington,Department of Economics
[3] Shandong Provincial Hospital Affiliated to Shandong First Medical University,Health Insurance Office
[4] Shanghai Jiao Tong University School of Medicine,Department of Endocrinology, Xinhua Hospital
[5] First Affiliated Hospital of Dalian Medical University,Department of Pharmacy
来源：
Health Economics Review | / 14卷
关键词：
Cost-effectiveness; Semaglutide; Sitagliptin; Type 2 diabetes; China;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
    Björn Eliasson
    Åsa Ericsson
    Adam Fridhammar
    Andreas Nilsson
    Sofie Persson
    Barrie Chubb
    PharmacoEconomics - Open, 2022, 6 : 343 - 354
  • [32] Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
    Eliasson, Bjorn
    Ericsson, Asa
    Fridhammar, Adam
    Nilsson, Andreas
    Persson, Sofie
    Chubb, Barrie
    PHARMACOECONOMICS-OPEN, 2022, 6 (03) : 343 - 354
  • [33] Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
    Capehorn, Matthew
    Hallen, Nino
    Baker-Knight, James
    Glah, Divina
    Hunt, Barnaby
    DIABETES THERAPY, 2021, 12 (02) : 537 - 555
  • [34] Once-weekly semaglutide vs existing once-weekly glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of Type 2 diabetes: Long-term cost-effectiveness analyses in the UK setting
    Viljoen, A.
    Hoxer, C. S.
    Johansen, P.
    Malkin, S. J. P.
    Hunt, B.
    Bain, S. C.
    DIABETIC MEDICINE, 2019, 36 : 134 - 134
  • [35] EVALUATING THE COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS EMPAGLIFLOZIN 25 MG FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN THE UK SETTING
    Capehorn, M.
    Hallen, N.
    Hunt, B.
    VALUE IN HEALTH, 2020, 23 : S512 - S512
  • [36] Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
    Matthew Capehorn
    Nino Hallén
    James Baker-Knight
    Divina Glah
    Barnaby Hunt
    Diabetes Therapy, 2021, 12 : 537 - 555
  • [37] Long-Term Effectiveness Associated with Maintenance Doses of Once-Weekly Semaglutide in US Adults with Poorly Controlled Type 2 Diabetes
    Tan, Xi
    Cao, Yiwen
    Dunn, Tyler J.
    Liang, Yuanjie
    Noone, Joshua
    Gamble, Cory L.
    King, Aaron A.
    DIABETES, 2024, 73
  • [38] Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes
    Tan, Xueying
    Cao, Xiaojing
    Zhou, Minzhi
    Zou, Ping
    Hu, Jingbo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (09) : 1083 - 1089
  • [39] Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK
    Marc Evans
    Sasha Berry
    Samuel J. P. Malkin
    Barnaby Hunt
    Abheet Sharma
    Diabetes Therapy, 2023, 14 : 1005 - 1021
  • [40] Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK
    Evans, Marc
    Berry, Sasha
    Malkin, Samuel J. P.
    Hunt, Barnaby
    Sharma, Abheet
    DIABETES THERAPY, 2023, 14 (06) : 1005 - 1021
12345